



## Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

April 23, 2019

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (NYSE/TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co. Healthcare Investor Conference taking place April 30-May 1, 2019 in Toronto, Canada.

The Company's presentation will be April 30, 2019 at 10:00 a.m. ET.

Interested parties can access a live webcast of the presentation via a link from Zymeworks' website at <http://ir.zymeworks.com/events-and-presentations>, which will also host a recorded replay available afterwards.

### About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company's suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2 clinical development. The Company's second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks' proprietary ZymeLink™ cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through multiple strategic partnerships with eight global biopharmaceutical companies. For more information, visit [www.zymeworks.com](http://www.zymeworks.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20190423005264/en/): <https://www.businesswire.com/news/home/20190423005264/en/>

### Zymeworks Inc.

Investor Inquiries:  
Ryan Dercho, Ph.D.  
(604) 678-1388  
[\[email protected\]](mailto:ryan.dercho@zymeworks.com)

Tiffany Tolmie  
(604) 678-1388  
[\[email protected\]](mailto:tiffany.tolmie@zymeworks.com)

Media Inquiries:  
Angela Bitting  
(925) 202-6211  
[\[email protected\]](mailto:angela.bitting@zymeworks.com)

Source: Zymeworks Inc.